AZD-2811 is under clinical development by AstraZeneca and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AZD-2811’s likelihood of approval (LoA) and phase transition for Small-Cell Lung Cancer took place on 13 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AZD-2811 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AZD-2811 overview

AZD-2811 is under development for the treatment of small-cell lung cancer. It is administered through intravenous route in the form of suspension. The drug candidate is an accurin containing AZD1152-hQPA, which acts by targeting aurora kinase B. It is based on Medicinal Nanoengineering platform. It was also under development for diffuse large B-cell lymphoma, and naive myelodysplastic syndrome.

It was under development for the treatment of hematological malignancies including treatment-naive and relapsed or refractory acute myeloid leukemia and solid tumors.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

Quick View AZD-2811 LOA Data

Report Segments
  • Innovator
Drug Name
  • AZD-2811
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: AstraZeneca
  • Originator: BIND Therapeutics
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.